BS_RVSEDNJ4
Ganglioglioma
Clinical attributes
From the source cohort, normalized into canonical keys plus the project's native columns.
- cancer_type
- Ganglioglioma
- cancer_type_detailed
- —
- subtype
- —
- cancer_type
- Ganglioglioma
- overall_survival_months
- 31.898817345597895
- age_years
- 14.271
- sex
- Male
GSVA pathway preview (50 Hallmark scores)
Top 10 most elevated and top 10 most suppressed Hallmark pathways for this sample.
Top 10 elevated
- PROTEIN_SECRETION+0.421
- OXIDATIVE_PHOSPHORYLATION+0.338
- ANDROGEN_RESPONSE+0.313
- ADIPOGENESIS+0.223
- MTORC1_SIGNALING+0.207
- UNFOLDED_PROTEIN_RESPONSE+0.203
- CHOLESTEROL_HOMEOSTASIS+0.202
- BILE_ACID_METABOLISM+0.188
- HEME_METABOLISM+0.177
- FATTY_ACID_METABOLISM+0.165
Top 10 suppressed
- EPITHELIAL_MESENCHYMAL_TRANSITION-0.381
- E2F_TARGETS-0.371
- G2M_CHECKPOINT-0.360
- PANCREAS_BETA_CELLS-0.301
- ANGIOGENESIS-0.252
- REACTIVE_OXYGEN_SPECIES_PATHWAY-0.240
- ALLOGRAFT_REJECTION-0.222
- DNA_REPAIR-0.217
- WNT_BETA_CATENIN_SIGNALING-0.190
- COAGULATION-0.166
Patient twins — nearest pathway neighbors
10 samples closest to this one in 50-dim pathway space, drawn from the Pathway Atlas. Cosine similarity = 1 means identical pathway state.
2 twins match this tumor's tissue · 8 come from a different tissue of origin ← cross-tissue dominant
| # | Sample | Cancer type | Subtype | cos similarity |
|---|---|---|---|---|
| 1 | BS_DPF1CX0G | pilocytic astrocytoma | — | 0.843 |
| 2 | BS_17WYVEEC | pilocytic astrocytoma | — | 0.826 |
| 3 | BS_52DAPP1Y | low-grade glioma | — | 0.822 |
| 4 | SJEPD030908_D1.RNA-Seq | EPN | Posterior Fossa EPN | 0.758 |
| 5 | BS_N210XMKR | low-grade glioma | — | 0.754 |
| 6 | BS_PEP9NZXN | low-grade glioma | — | 0.732 |
| 7 | BS_66ABA973 | pilocytic astrocytoma | — | 0.729 |
| 8 | SJEPD031750_D1.RNA-Seq | EPN | Posterior Fossa EPN | 0.725 |
| 9 | SRR6013579 | — | cohortA1 | 0.715 |
| 10 | TCGA-44-2666-01A-01R-A278-07 | — | cohortMD2 | 0.706 |
Per-pathway drug coverage
For each elevated pathway in this tumor, the best-reversing drug across the catalog. Uncovered pathways = unmet need at pathway level for this one patient.
0 of 22 elevated pathways have at least one drug that meaningfully reverses them.
| Pathway (elevated) | tumor score | Best drug | reversal magnitude |
|---|---|---|---|
| PROTEIN_SECRETION | 0.421 | Remibrutinib | — uncovered |
| OXIDATIVE_PHOSPHORYLATION | 0.338 | Remibrutinib | — uncovered |
| ANDROGEN_RESPONSE | 0.313 | Inavolisib | — uncovered |
| ADIPOGENESIS | 0.223 | Inavolisib | — uncovered |
| MTORC1_SIGNALING | 0.207 | Inavolisib | — uncovered |
| UNFOLDED_PROTEIN_RESPONSE | 0.203 | Idelalisib | — uncovered |
| CHOLESTEROL_HOMEOSTASIS | 0.202 | Remibrutinib | — uncovered |
| BILE_ACID_METABOLISM | 0.188 | Inavolisib | — uncovered |
| HEME_METABOLISM | 0.177 | Temsirolimus | — uncovered |
| FATTY_ACID_METABOLISM | 0.165 | Inavolisib | — uncovered |
| TGF_BETA_SIGNALING | 0.141 | Inavolisib | — uncovered |
| INTERFERON_ALPHA_RESPONSE | 0.135 | Inavolisib | — uncovered |
| TNFA_SIGNALING_VIA_NFKB | 0.126 | Inavolisib | — uncovered |
| P53_PATHWAY | 0.116 | Idelalisib | — uncovered |
| UV_RESPONSE_DN | 0.108 | Inavolisib | — uncovered |
| MYC_TARGETS_V1 | 0.105 | Inavolisib | — uncovered |
| PEROXISOME | 0.099 | Idelalisib | — uncovered |
| KRAS_SIGNALING_UP | 0.054 | Inavolisib | — uncovered |
| XENOBIOTIC_METABOLISM | 0.040 | Inavolisib | — uncovered |
| HEDGEHOG_SIGNALING | 0.035 | Inavolisib | — uncovered |